Soleo Health Launches SoleoRare™ to Target Rare Disease Market
Event summary
- Soleo Health launched SoleoRare™, a dedicated Rare Disease Specialty Pharmacy, on April 20, 2026.
- The new brand consolidates experienced rare disease patient care, patient access, and commercial teams under a clinician-led, patient-centered model.
- Soleo Health operates 28 pharmacy locations with national nursing coverage and pharmacy licensure in all 50 states.
- The company is accredited by URAC, ACHC, and the National Association of Boards of Pharmacy for various specialty services.
The big picture
The launch of SoleoRare™ underscores the growing focus on specialized care for rare disease patients, a segment that demands higher clinical expertise and patient support. This move aligns with broader industry trends towards personalized medicine and the increasing investment in rare disease therapies. Soleo Health's extensive accreditation and national coverage position it to capitalize on this niche market, but success will depend on its ability to differentiate itself in a competitive landscape.
What we're watching
- Market Differentiation
- How SoleoRare™ will compete against established players in the rare disease specialty pharmacy space.
- Pharma Partnerships
- Whether SoleoRare™ can attract and retain pharmaceutical manufacturer partners developing rare and orphan therapies.
- Patient Outcomes
- The impact of SoleoRare™'s clinician-led, patient-centered model on patient outcomes and satisfaction.
Related topics